Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluproxiadine
- Development stage
- Unknown
- Lead developer
- Kobe City Medical Center General Hospital
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Fluproxiadine (also referred to as fluproxadine or AF78) is a fluorine-18 labeled positron emission tomography (PET) radiotracer designed to target the norepinephrine transporter (NET). Built on a phenethylguanidine scaffold, it exhibits high affinity and selectivity for NET, mimicking the physiological transport and storage kinetics of norepinephrine at sympathetic nerve terminals. It is developed for cardiac sympathetic nerve imaging, neurological imaging, and the delineation of neuroendocrine tumors such as pheochromocytoma and paraganglioma. The tracer features a streamlined, one-step radiosynthesis using an unprotected guanidine precursor, which facilitates automated clinical production. First-in-human studies have demonstrated its safety, favorable biodistribution, and clear myocardial visualization with acceptable radiation dosimetry.
- Other names
- 18F-AF7818F-fluproxadine18F-fluproxiadine[18F]AF78[18F]fluproxadine[18F]fluproxiadinefluproxadine
02
Targets
NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on fluproxiadine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluproxiadine.